Deals this week: Rox Medical, Acelity, Catalent

8 September 2016 (Last Updated September 8th, 2016 18:30)

In a series E financing round led by Novartis Venture Fund and Apple Tree Partners, Rox Medical, a medical device company specialising in developing technologies for hypertension, has secured $40m.

 

ROX Coupler

 

In a series E financing round led by Novartis Venture Fund and Apple Tree Partners, Rox Medical, a medical device company specialising in developing technologies for hypertension, has secured $40m.

The proceeds will be used to conduct a pivotal clinical trial in the US for ROX Coupler therapy, which is an alternative solution for uncontrolled hypertension.

A global advanced wound care and regenerative medicine company, Acelity, through its wholly-owned subsidiaries, Kinetic Concepts, and KCI USA, intends to raise $1.75bn through a private offering of second lien senior secured notes due 2021.

Gross proceeds from the offering together with proceeds of $100m offered by Acelity's sponsors and cash on hand, will be used to redeem the company’s second lien senior secured notes due 2018 and also to pay the fees and expenses related to other financing transactions.

Insulet Corporation, an insulin pump technologies developer, has announced private placement of convertible senior notes, due 2021, to raise gross proceeds of $250m. Initial purchasers will get an option to buy up to an additional $37.5m in principal amount of notes.

Part of the proceeds from the placement will be used to finance, redeem or settle the company’s convertible senior notes due 2019, while the remaining are planned to be used to invest in improving production and supply chain capabilities.

Catalent, a global drug delivery technologies provider, has announced a secondary public offering of its common stock. Shares of the company’s common stock worth $19m.

Catalent will not receive any gross proceeds from the sale, as it is not offering any of its stock.

"Catalent will not receive any gross proceeds from the sale, as it is not offering any of its stock."

Aequus Pharmaceuticals, a specialty pharmaceutical company, has signed an agreement with a syndicate of agents to offer between approximately 6.7 million and 13.3 of its common stock to public.

Expected to be closed on 13 September, the offering will raise gross proceeds between C$2m ($1.54m) and C$4m ($3.09m), which will be utilised by the company for general corporate purposes.

The shares are being offered in the Canadian provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, while the company also plans for a private placement in the US, pursuant to regulatory requirements.

The agents are allowed to optionally buy up to an additional 15% of the issue size, which is exercisable within 30 days of the issue closure.


Image: ROX Coupler is a small stent-like device used to establish connection between the artery and vein in the upper leg. Photo: ROX Medical.